Eli Lilly, BCE, Suncor, Canada Goose, Bombardier, Thomson Reuters and Lightspeed reported earnings this week. Here are the ...

Eli Lilly investors and analysts said they want ... citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi ...

making it one of the most extensive so far on a class of medicines that includes Novo Nordisk’s Wegovy and Eli Lilly & Co’s Zepbound. The study, published on Jan 20 in the journal Nature ...

UnitedHealth Group CEO says complex US healthcare system needs to change Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Your local pharmacy might be the next front in Donald Trump’s trade war. The president has in recent weeks promised to impose tariffs on all foreign-made medications, a move intended to encourage drug ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...